{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Hematology parameters assessment included white blood cell (WBC) count and differential (lymphocytes, monocytes, basophils, eosinophils, neutrophils), red blood cell (RBC) count, hematocrit, hemoglobin, and platelet count. Change From baseline in hematology parameters at Day 30 were reported.","groups":[{"description":"Participants received single dose of tinostamustine 180 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG000","title":"Tinostamustine 180 mg/m^2"},{"description":"Participants received single dose of tinostamustine 220 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG001","title":"Tinostamustine 220 mg/m^2"}],"populationDescription":"The study was early terminated on 17 April 2019, due to safety signals during Phase 1. Hence, data for this outcome measure was not collected as planned, analyzed and reported at specific time point.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -1), Day 30","title":"Phase 1 and 2: Change From Baseline in Hematology Parameters","type":"SECONDARY"}